CINCINNATI, Feb. 27 /PRNewswire-FirstCall/ -- Kendle , a leading, global full-service clinical research organization (CRO), today announced plans to expand its global clinical development operation further into the Asia/Pacific region and Latin America through two new operating units focused on Phase I-III services in these high-growth markets. Leadership for these units will be provided by Sarah Beeby and Dennis Hurley, DrSc, who will serve as Vice President, Global Clinical Development - Asia/Pacific and Vice President, Global Clinical Development - Latin America, respectively. Beeby and Hurley are charged with targeting new geographies for expansion in their respective regions.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO)
"Delivery of Phase I-III global clinical development services is a core competency for Kendle," said Candace Kendle, PharmD, Chairman and Chief Executive Officer. "This move further enhances Kendle's position to serve our customers in these developing regions and capitalize on the tremendous market opportunity for Phase I-III clinical development services globally, which is estimated to reach $3.6 billion this year." She continued, "We look forward to Sarah's and Dennis' leadership as we strengthen our position in these important markets."
Kendle has been active in the Asia/Pacific region and in Latin America since 1998 and 2003, respectively. The company's existing operations include China, Australia and India in Asia/Pacific and Mexico and Peru in Latin America.
Beeby joined Kendle in 2001 as Assistant Director, Clinical Services, responsible for the clinical monitoring function across Europe. Most recently she served as Director, Strategic Business Services, Europe, leading the company's expansion in the developing regions of Central and Eastern Europe, India and South Africa, where the company has experienced significant growth. Prior to joining Kendle, Beeby spent seven years in clinical research positions in the pharmaceutical and CRO industries. She earned a bachelor of science in animal physiology from Queen Mary & Westfield College, University of London.
Hurley joined Kendle in 2003 as Vice President, Latin America, in conjunction with the company's acquisition of Mexico CRO Estadisticos y Clinicos Asociados, S.A (ECA). Hurley co-founded ECA, the largest Phase I-IV CRO in Mexico and the second largest in Latin America, in 1987. Since joining Kendle, he has been instrumental in establishing the company in the region. Hurley has more than 20 years of CRO experience in Latin America and the United States, including positions in biostatistics, quality assurance and project management. He completed a post-doctorate in biostatistics at the University of North Carolina at Chapel Hill.
About Kendle
Kendle International Inc. is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our nearly 2,000 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202 or from the company's Web site at www.kendle.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comKendle International Inc.CONTACT: Investors, Patty Frank, +1-513-763-1992, or Media, Lori Dorer,+1-513-345-1685, both of Kendle International Inc.
Web site: http://www.kendle.com/
